China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
114 hedge funds and large institutions have $2.67B invested in China Biologic Products Holdings, Inc. in 2015 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 31 increasing their positions, 45 reducing their positions, and 20 closing their positions.
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
73% more capital invested
Capital invested by funds: $1.54B → $2.67B (+$1.12B)
45% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 20
10% more call options, than puts
Call options by funds: $8.43M | Put options by funds: $7.65M
8% more funds holding
Funds holding: 106 → 114 (+8)
31% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$92.7M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$37.5M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$35.3M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
+$20M |
| 5 |
ICP
Indus Capital Partners
New York
|
+$17.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$30.2M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
-$16.3M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$12.8M |
| 4 |
Two Sigma Investments
New York
|
-$11.2M |
| 5 |
VAM
Visium Asset Management
New York
|
-$10.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NEI
126
Northwest & Ethical Investments
Toronto,
Ontario, Canada
| – | -$277K | -3,080 | Closed |
|
|
CG
127
Clinton Group
New York
| – | -$223K | -2,479 | Closed |
|
128
Walleye Trading
New York
| – | -$108K | -1,200 | Closed |
|
|
SEC
129
Seven Eight Capital
New York
| – | -$36K | -400 | Closed |
|
|
TRCT
130
Tower Research Capital (TRC)
New York
| – | -$21K | -230 | Closed |
|
131
Nomura Holdings
Tokyo,
Japan
| – | -$18K | -213 | Closed |
|
|
RFS
132
Rockefeller Financial Services
New York
| – | -$19K | -207 | Closed |
|
133
Creative Planning
Overland Park,
Kansas
| – | -$10K | -115 | Closed |
|
|
JIM
134
Jupiter Investment Management
London,
United Kingdom
| – | +$2.75M | +23,800 | New |
|
CBPO Hedge Fund Activity: Q4 2015 in Review
114 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q4 2015, worth a combined $2.67B — up 73% from $1.54B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CBPO positions and 20 closed out — a net gain of 9 holders — while 31 added to existing stakes and 45 trimmed.
The largest buyer was Capital World Investors, adding an estimated $92.7M. The largest seller was Ameriprise, cutting an estimated $30.2M.
- 114 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q4 2015, up from 106 in Q3 2015.
- Funds reported $2.67B of China Biologic Products Holdings, Inc. stock for Q4 2015, up 73% quarter-over-quarter.
- 29 funds opened new China Biologic Products Holdings, Inc. positions in Q4 2015 and 20 closed out, a net change of +9 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q4 2015 was Capital World Investors, an estimated $92.7M added.
- The largest China Biologic Products Holdings, Inc. seller in Q4 2015 was Ameriprise, an estimated $30.2M sold.
Based on aggregated 13F filings for Q4 2015.